Joselyn Cruz-Cruz

Also affiliated with Center for Cancer and Blood Disorders, University of Colorado Anschutz Medical Campus, University of Colorado Denver

MedicineImmunology and MicrobiologyNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation”.

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005871

N/A

0DataRank · unranked

62 citations

Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Blümel +33 more

Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009221

N/A

0DataRank · unranked

16 citations

Elena Woods, Eric Hoffmeyer, K Schaller, Joselyn Cruz-Cruz, Joseph Fernandez +7 more